Small molecule · Degrader of Estrogen receptor alpha (ESR1) · developed by Olema Pharmaceuticals
Palazestrant is an orally available small molecule that binds the ligand pocket of estrogen receptor alpha (ESR1), competing with estradiol, and acts as a selective estrogen receptor degrader that induces ERalpha degradation. It is being studied in breast cancer, including ER-positive, HER2-negative disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06016738 | Phase 3 | Breast Cancer | Active not recruiting | OLMA |
| NCT04505826 | Phase 1/2 | Hormone Receptor Positive Breast Carcinoma | Completed | OLMA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Breast CancerBreast CancerER Positive Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the OLMA page.
See OLMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OLMA catalysts and pipeline →